ClinicalTrials.gg
CompletedNCT05685615Updated Jan 14, 2025

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

A Phase 2 interventional study of BV100 plus Polymyxin B and BAT in Ventilator Associated Pneumonia, sponsored by BioVersys AG. Completed at 16 sites in 3 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by BioVersys AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB

Read the detailed description

A multicenter, open label, randomized, active controlled, Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B versus best available therapy in adult patients with ventilator associated bacterial pneumonia suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii

02

Conditions studied

  • Ventilator Associated Pneumonia
03

In context

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

This study's enrollment of 39 is below the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.

Browse Pneumonia, Ventilator-Associated studies →

Lead sponsor

BioVersys AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet all the following diagnostic and clinical criteria are eligible for the study:

  1. Provide written prior to any study related procedures not part of normal medical care. Surrogate consent/use of a legally authorized representative may be provided, if permitted by local country and institution specific guidelines. If a patient regains consciousness while in the study and, per the Investigator's judgment, the patient is able to read, assess, understand, and make his/her own decision to participate in the trial, the patient can agree to continue participation and the patient should be re consented, if required by local country and institution specific guidelines.
  2. Male or female patients ≥ and \< 80 years of age at the time of Informed Consent Form (ICF) signing with a (BMI) of \< 40 kg/m2 at the time of ICF signing.
  3. Hospitalized for ≥ 48 hours, intubated (via endo or nasotracheal tube, including tracheostomy patients) and receiving mechanical ventilation for ≥ 48 hours at the time of randomization, and with acute changes made in the ventilator support system to enhance oxygenation, as determined by arterial blood gas, or worsening PaO2/FiO2 ratio.
  4. All patients must have a chest radiograph or a lung CT scan within 48 hours prior to randomization showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia (based on Investigator's evaluation).
  5. Clinical findings to support diagnosis of VABP. At least 1 of the following must be documented to be present within 24 hours prior to randomization:

    • Documented fever (oral ≥ 38.0 °C [100.4 °F] or a tympanic, temporal, rectal, or core temperature ≥ 38.3 °C [101.0 °F], axillary or forehead scanner ≥ 37.5 °C [99.5 °F]) OR
    • Hypothermia (rectal/core body temperature ≤ 35.0 °C [95.2 °F]), OR
    • Leukocytosis with total peripheral white blood cell count (WBC) ≥ 10 000 cells/mm3, OR
    • Leukopenia with total peripheral WBC count ≤ 4500 cells/mm3.
  6. Acute Physiology and Chronic Health Evaluation (APACHE II) score between 8 and 30, inclusive, within 24 hours prior to randomization. Any data collected before ICF signature as part of a routine standard for patient care (e.g., laboratory values, Glasgow Coma Score, Acute Physiology Score [APS]) can be used for Screening Visit assessment, if applicable, without repeating the assessments.
  7. High probability of pneumonia due to A. baumannii, defined as follows:

    • RDT, performed within 36 hours prior to randomization, using an acceptable respiratory sample (PBS, BAL, mini BAL, or ETA) positive for A. baumannii, OR
    • A surveillance culture from a respiratory sample positive for A. baumannii within 72 hours prior to randomization.

Part B specific:

  1. Patients who have been treated previously with an empiric antibiotic regimen and have failed treatment, both clinically and microbiologically, if they have an identified CRAB which has been shown to be non-susceptible in vitro to each of the antibiotic(s) of the empiric antibiotic regimen or has been identified from a culture performed after at least 48 hours of empiric antibiotic regimen, AND/OR
  2. Has an infection caused by A. baumannii organisms known to be resistant to colistin (defined as MIC ≥ 4 mg/L by a non-agar-based method) based on evidence from culture or susceptibility testing after at least 48 hours of antibiotic treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria are not eligible to participate in this study:

    1. Known or suspected community acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia.
    2. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure ≥ 60 mmHg
    3. Known or suspected allergy to polymyxin, rifabutin, BAT, or their .
    4. Any of the following health conditions:

      • Confirmed legionella infection (Legionella pneumophila pneumonia), Aspergillus spp. pneumonia (testing is not required)
      • Candida spp. infection requiring systemic treatment
      • Cystic fibrosis
      • Known or suspected Pneumocystitis jiroveci pneumonia
      • Known or suspected active tuberculosis
      • Lung abscess
      • Solid organ transplant within 6 months prior to randomization
      • Pleural empyema
      • Evidence of deep seated infection outside the respiratory tract, e.g., endocarditis, osteomyelitis.
      • Known or suspected neuropathy or neuromuscular disease
      • Known infection
    5. Bronchial obstruction or a history of post obstructive pneumonia (this does not exclude patients with pneumonia who have an underlying ).
    6. Acute Grade ≥ 3.
    7. Expected survival \< 72 hours or a Do Not Resuscitate Order.
    8. Burns > 40% of total body surface area.
    9. Current or anticipated neutropenia with \< 1000 cells/mm3.
    10. Severe renal disease defined as an estimated as per Cockcroft Gault (CLCR CG) \< 30 mL/minute or estimated glomerular infiltration rate () as per Modified Diet in Renal Disease (MDRD) equation \< 30 mL/min/1.73 m2, or requirement for peritoneal dialysis, hemodialysis, hemofiltration, or a urine output \< 20 mL/hour over a 24 hour period.
    11. (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or (conjugated/unconjugated) ≥ 3 × (ULN) values used by the laboratory performing the test or Class B and C in patients with chronic liver function impairment. Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis, hepatic cirrhosis, hepatic failure, chronic ascites, or hepatic encephalopathy.
    12. Received systemic or inhaled antibiotic therapy potentially effective against A. baumannii within 72 hours prior to randomization for ≥ 36 hours
    13. Investigator's opinion of (ECG) finding such as new ischemic changes, infarct, or ventricular arrhythmia with immediate potential for a fatal outcome, bradycardia not corrected by pacemaker or medication, or, prior to the current infection, a history of (NYHA) Class IV cardiac failure defined as severe limitations - experiences symptoms even while at rest, mostly bedbound patients, within 1 year.
    14. Abnormal corrected by Fridericia (QTcF): > 450 ms confirmed with repeat ECG.
    15. Stroke (ischemic or intracerebral hemorrhage) within 5 days prior to randomization.
    16. Women who are pregnant or nursing, or who are of and unwilling to use an acceptable method of (e.g., intra-uterine device [IUD], male partner sterilization, or complete sexual abstinence) for at least 30 days after the last dose of the study drug. Negative pregnancy test should be obtained before randomization. The following women are not considered to have childbearing potential: 1) those who have undergone surgical sterilization, including hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy, but excluding bilateral tubal occlusion; 2) age ≥ 50 and as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments.
    17. Male patients with female partners of childbearing potential who are unwilling to use 2 methods of contraception, one of which must be a barrier method (e.g., condom), for at least 30 days after the last dose of study drug.
    18. Previous exposure to BV100.
    19. Patients who are currently enrolled in or have not yet completed at least 30 days since ending another device or drug trial or are receiving other investigational agents.
    20. Not willing to comply with all study procedures.
    21. Confirmed or suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on local standard-of-care assessments available during Screening, unless the suspected A. baumannii pneumonia is diagnosed 14 days or more after the detection of SARS CoV 2.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    BV100 (200 mg) plus Polymyxin B

    BV100 (200 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h

    Drug: BV100 plus Polymyxin B

  • Experimental
    BV100 (300 mg) plus Polymyxin B

    BV100 (300 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h

    Drug: BV100 plus Polymyxin B

  • Active comparator
    Best Available Therapy

    Best Available Antibiotic Therapy to Treat CRAB

    Drug: BAT

  • Experimental
    Part B: BV100 plus BAT

    BV100 (300 mg q12h) infused over 2 hours plus Best Avaialble Therapy to Treat Colistin resistant CRAB

    Drug: BAT

Interventions

  • DrugBV100 plus Polymyxin B

    Drug pages: BV100 · Polymyxin B

    Rifabutin for Infusion plus Polymyxin B for Injection

  • DrugBAT

    The best avaialble antibiotic therapy to treat CRAB

    Also known as: Best Avaialble Therapy

06

What researchers measure

Primary outcomes

  1. To investigate the pharmacokinetic (PK) properties of BV100 co administered with Polymyxin B during 7 to 14 days of treatment in patients with ventilator associated bacterial pneumonia (VABP)

    Maximum Observed Plasma Concentration (Cmax) of rifabutin

    Time frame: 14 days

  2. To investigate the pharmacokinetic properties of BV100 co administered with Polymyxin B during 7 to 14 days of treatment in patients with ventilator associated bacterial pneumonia (VABP)

    Area Under the Plasma Concentration-Time Curve (AUC) of rifabutin

    Time frame: 14 days

Secondary outcomes

  1. To assess the 28 day ACM rates of BV100 plus Polymyxin B compared to best available therapy (BAT)

    28 Day ACM

    Time frame: 28 Days

  2. To assess the 14 day ACM rates of BV100 plus Polymyxin B compared to best available therapy (BAT)

    14 Day ACM

    Time frame: 14

  3. To assess safety and tolerability of BV100 plus Polymyxin B compared to best available therapy (BAT)

    Number of Participants with Treatment-Emergent Adverse Events

    Time frame: 28 days

07

Study locations

16 sites
  • Academician Vakhtang Bochorishvili Clinic
    Tbilisi, Georgia
  • Eristavi National Center of Experimental and Clinical Surgery
    Tbilisi, Georgia
  • First University Clinic of Tbilisi State Medical University
    Tbilisi, Georgia
  • Gudushauri National Medical Center
    Tbilisi, Georgia
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center
    Tbilisi, Georgia
  • Number 5 Clinical Hospital
    Tbilisi, Georgia
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
    Tbilisi, Georgia
  • General Hospital of Athens "Evangelismos"
    Athens, Greece
  • University General Hospital "Attikon"
    Athens, Greece
  • General University Hospital of Heraklion
    Heraklion, Greece
  • General Hospital of Larissa
    Larissa, Greece
  • University General Hospital of Larissa
    Larissa, Greece
  • General Hospital of Thessaloniki "Ippokratio"
    Thessaloníki, Greece
  • University of Debrecen Clinical Center
    Debrecen, Hungary
  • University Educational Hospital
    Miskolc, Hungary
  • Fejer County St. Gyorgy University Teaching Hospital
    Szekesfehervar, Hungary
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Nov 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 17, 2023
StartActual
Apr 20, 2023
Primary completionActual
Nov 1, 2024
CompletionActual
Dec 11, 2024
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05685615
Lead sponsor
BioVersys AG
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Apr 20, 2023
Primary completion
Nov 1, 2024
Completion
Dec 11, 2024
Last update
Jan 14, 2025

Study contacts

Lisa Husband, MD
study director · BioVersys SAS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BV100 · Polymyxin B

Start the discussion